Antiviral
-
In the neverending human-vs-virus battle, scientists often focus on disrupting the protein coating on the bugs. New research shows an alternative: using certain compounds to act as molecular "pins" that pop the membranes holding viruses together.
-
A rolling compressor from Japan has extracted water from plants without the need for a heat source, creating water-soluble antiviral compounds from cedar and ginger while turning the plants into clean, efficient fuels.
-
While most of us wouldn't dream of not washing our spoons or forks after each use, we have no problem repeatedly using – or sharing – a never-washed tube of lipstick. That's why scientists have developed a cranberry-fortified antimicrobial lipstick.
-
Although there are coatings that kill harmful microbes on frequently touched surfaces, most of those substances either have to be frequently reapplied, or they take a long time to work. A new coating, however, is claimed to address both shortcomings.
-
Copper is known for its ability to kill microbes on contact, which is why it's often professionally coated onto commonly touched items. A copper nanowire spray may allow everyday folks to give existing surfaces the same treatment, using a spray can.
-
The FDA issued emergency use authorization to a second oral COVID-19 treatment. Molnupiravir is not as effective as Pfizer’s recently approved COVID pill and experts are concerned the drug has the potential to generate new SARS-CoV-2 variants.
-
The first oral treatment designed specifically for COVID-19 has been authorized for use in the US by the FDA. Called Paxlovid, the treatment is recommended for those at high risk of severe COVID-19 and is to be taken within five days of symptom onset.
-
Positive data has been announced from a trial testing Pfizer’s antiviral pill developed to treat COVID-19. The final analysis revealed the five-day oral treatment reduced COVID-related hospitalizations and deaths by 89 percent in high-risk individuals.
-
Ahead of a FDA advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19. The new data reveals the treatment is significantly less effective than early indications.
-
Pfizer’s experimental COVID-19 antiviral pill has shown extraordinary efficacy in the first data from a large clinical trial. The results reveal the oral treatment reduces hospitalization or death in high-risk patients by 89 percent compared to placebo.
-
As the US Government invests billions of dollars into COVID-19 antiviral research, scientists are racing to develop a pill that people can take at home to treat the disease in its earliest stages.
-
If there's one place where you don't want viruses or harmful bacteria to be present, it's in hospitals, where people are already vulnerable. A new process could help, by allowing aluminum surfaces in such buildings to kill the bugs.
Load More